Stability of long-term therapeutic responses to tralokinumab in adults with moderate-to-severe atopic dermatitis

Andrew Blauvelt,

H. Chih-ho Hong,

Ketty Peris,

Norito Katoh,

Marie Tauber,

Mahreen Ameen,

Melinda Gooderham,

Christian Bjerregård Øland,

Ann-Marie Tindberg,

Le Gjerum,

Kristian Reich

Oregon Medical Research Center, Portland, OR, USA; University of British Columbia, Vancouver, BC, Canada; Dermatologia, Università Cattolica del Sacro Cuore, Rome, Italy; Kyoto Prefectural University of Medicine Graduate School of Medical Science, Japan; Department of Allergology and Clinical Immunology, Lyon Sud hospital and Inserm U1111 CIRI, Lyon, France; Royal Free London National Health Services Foundation Trust, London, UK; SKiN Centre for Dermatology, Peterborough, ON, Canada; Department of Dermatology, Queen’s University, Kingston, ON, Canada; LEO Pharma A/S, Ballerup, Denmark; Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Introduction/Background: To ensure minimal residual disease and to prevent relapses, recently published consensus reports have defined optimal long-term treatment targets for atopic dermatitis (AD).\textsuperscript{1,2} Tralokinumab, a monoclonal antibody specifically neutralizing interleukin-13, is approved for the treatment of moderate-to-severe AD. ECZTEND (NCT03587805) is an ongoing open-label, 5-year extension trial investigating the long-term safety and efficacy of tralokinumab 300 mg every other week (Q2W) plus optional topical corticosteroids (TCS).

Objectives: To determine the proportion of patients treated for up to 4 years with tralokinumab in AD clinical trials who: 1) exhibit stable improvement, with no or minimal fluctuations, in lesion
extent and severity long-term (ie, response in \( \geq 80\% \) of attended visits), and 2) exhibit a stable long-term composite response (ie, up to 4 years of tralokinumab treatment and response in \( \geq 80\% \) of attended trial visits) in signs and symptoms of AD, and quality of life based on recent treat-to-target recommendations (EASI \( \leq 7 \) and either DLQI \( \leq 5 \) or Itch NRS \( \leq 4 \)).

**Methods:** This *post hoc* analysis included 347 patients who were continuously treated with tralokinumab for 52 weeks in the identically designed phase 3 monotherapy trials ECZTRA 1&2 and subsequently for up to 152 weeks in ECZTEND as of the April 30, 2022 data cutoff. Stability of long-term response, with no or minimal fluctuations, was defined as meeting the target endpoints at \( \geq 80\% \) of attended visits between Weeks 16-152 in ECZTEND. Endpoints analyzed were EASI \( \leq 7 \), EASI \( \leq 2 \), and a composite long-term treatment target: EASI \( \leq 7 \) and either DLQI \( \leq 5 \) or worst weekly pruritus NRS \( \leq 4 \).

**Results:** A stable EASI \( \leq 7 \) response (at \( \geq 80\% \) of attended visits) was observed in 70.2\% (233/332) of tralokinumab-treated patients over Weeks 16-152 of ECZTEND. A stable EASI \( \leq 2 \) response was observed in 34.0\% (113/332) of patients, and a long-term optimal composite target, EASI \( \leq 7 \) and either DLQI \( \leq 5 \) or Itch NRS \( \leq 4 \), was observed in 60.5\% (201/332) of patients.

**Conclusions:** High proportions of clinical trial patients maintained stable responses, with no or minimal fluctuations in efficacy, with continued tralokinumab 300 mg Q2W plus optional TCS for up to 4 years of treatment.

**References:**


**Keywords:** atopic dermatitis, tralokinumab, IL-13, long-term
Acknowledgements:

This ECZTEND trial was sponsored by LEO Pharma A/S (Ballerup, Denmark). Medical writing and editorial support from Alphabet Health (New York, NY) by Juliel Espinosa, PhD, was funded by LEO Pharma A/S. This work was previously presented at AAD 2024, San Diego, CA, March 8-12, 2024.

Disclosures:

**AB** has served as a speaker (received honoraria) for AbbVie, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Regeneron, and Sanofi, served as a scientific adviser (received honoraria) for AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Dermavant, EcoR1, Eli Lilly and Company, Escient, EVELO, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnovenBio, Janssen, Landos, Leo, Merck, Novartis, Pfizer, Rani, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, TLL Pharmaceutical, TrialSpark, UCB Pharma, Union, Vibliome, and Xencor, and has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelrylin, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Concert, Dermavant, Eli Lilly and Company, EVELO, Evommune, Galderma, Incyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sun Pharma, and UCB Pharma.

**HCH** is a researcher, consultant, and/or advisor for AbbVie, Amgen, Arcutis, Bausch Health, Boehringer Ingelheim, Celgene, Dermavant, Dermira, DS Biopharma, Galderma, GlaxoSmithKline, Incyte, Janssen, LEO Pharma, Lilly, MedImmune, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, and UCB.
KP reports grants or personal fees for participation in advisory boards from AbbVie, Almirall, Galderma, Lilly, LEO Pharma, Novartis, Pierre Fabre, Sanofi, Sun Pharma, and Janssen.

NK has received honoraria as a speaker/consultant for Sanofi, Maruho, AbbVie, Eli Lilly Japan, Mitsubishi Tanabe Pharma, Jansen Pharma, Taiho Pharmaceutical, Torii Pharmaceutical, Kyowa Kirin, Celgene Japan, and LEO Pharma, and has received grants as an investigator from Maruho, Eli Lilly Japan, Sun Pharma, Taiho Pharmaceutical, Torii Pharmaceutical, Boehringer Ingelheim Japan, Kyowa Kirin, Jansen Pharma, Eisai, A2 Healthcare, AbbVie, and LEO Pharma.

MT has served as an investigator for AbbVie, Boehringer Ingelheim, Eli Lilly, Galderma, LEO Pharma, Pierre Fabre, and Sanofi-Regeneron; a consultant or advisory board for Sanofi-Regeneron, AbbVie, Eli Lilly, MEDAC, Jansen Pharma and Almirall.

MA has served as a consultant and/or scientific advisor and/or principal investigator of clinical trials with Regeneron, Sanofi Genzyme, LEO, Pfizer, Abbvie, and Eli Lilly.

MG has been an investigator, speaker and/or advisor for: AbbVie, Amgen, Akros, AnaptysBio, Aslan, Arcutis, Aristeia, Bausch Health, BMS, Boehringer Ingelheim, Celgene, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Incyte, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Merck, Meiji, Moonlake, Nimbus, Novartis, Pfizer, Reistone, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, and UCB.

CBØ, AT, and LG are employees and shareholders of LEO Pharma A/S.

KR has served as advisor and/or paid speaker for and/or participated in clinical trials sponsored by Abbvie, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Forward Pharma, Gilead, Galderma, Janssen-Cilag, Kyowa Kirin, Leo, Lilly, Medac, Novartis, Ocean Pharma, Pfizer, Sanofi, UCB; Professor Reich is co-founder of Moonlake Immunotherapeutics.